endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

Blue­bird bio dives deep­er in­to its TCR al­liance with Medi­gene, adding $500M in mile­stones and 2 new tar­gets

8 years ago
R&D
Pharma

CRISPR trail­blaz­ers Zhang, Liu and Joung join forces to launch Beam with $87M and cut­ting-edge gene-edit­ing tech

8 years ago
Financing
Startups

Trump's 'sweep­ing ac­tion' to low­er drug prices mocked by an­a­lysts as re­lieved in­vestors trig­ger ral­ly in Big Phar­ma ...

8 years ago
Pharma

Sen­a­tors Wyden, Mur­ray launch No­var­tis probe: 'What Amer­i­ca has seen here rais­es the specter of cor­rup­tion'

8 years ago
Pharma

Celldex ax­es two more pro­grams to cut costs fol­low­ing glem­bat­u­mum­ab fail­ure; Zio­pharm stock slides on halt­ed brain ...

8 years ago
News Briefing

Jose Car­los 'JC' Gutiér­rez-Ramos hits the ex­it at Syn­log­ic; Rich Hey­man pass­es Oric reins to ex-Igny­ta CFO

8 years ago
Peer Review

Whisky, se­crets, and code names: be­hind-the-scenes of Takeda's $62B Shire bid - Bloomberg

8 years ago
Deals

Akari CEO Horn Solomon oust­ed af­ter al­leged­ly abus­ing the com­pa­ny cred­it card

8 years ago
People

La Jol­la grabs $125M roy­al­ty deal to back drug launch, fund R&D

8 years ago
Pharma

Trump is kick­ing the can down the road to­day, avoid­ing any tough pre­scrip­tions on drug pric­ing

8 years ago
Bioregnum
Opinion

As­traZeneca's star res­pi­ra­to­ry drug runs in­to an­oth­er wall with COPD, but it's not giv­ing up — yet

8 years ago
R&D

Akcea, Io­n­is win over most FDA ex­perts to their rare dis­ease drug volane­sors­en, vast­ly im­prov­ing odds of suc­cess

8 years ago
Pharma

Chi­na's CStone bags $260M Se­ries B for am­bi­tious I/O work, ex­pand­ing its list of mar­quee in­vestors

8 years ago
Financing
China

Astel­las signs Asian li­cens­ing deal with Aquinox; Ar­a­vive touts ear­ly-stage PoC

8 years ago
News Briefing

Eight years af­ter Eli Lil­ly dumped it, an up­start biotech has nabbed teplizum­ab and filed a $56M IPO to back a PhI­II ...

8 years ago
Financing
Startups

Hunt­ing a cure, Ex-No­var­tis ex­ec Bas­tiano San­na takes the reins at Cam­bridge di­a­betes start­up Sem­ma

8 years ago
People

Lit­tle vTv once again cir­cles sub­group num­ber, strug­gling to find some­thing good to say about failed Alzheimer's drug

8 years ago
R&D

Play­ing catch-up, Eli Lil­ly swoops in with $1.6B cash deal for Ar­mo Bio and its promis­ing PhI­II can­cer drug

8 years ago
Deals

Roche's big PhI­II Tecen­triq/Cotel­lic com­bo study for colon can­cer fails, dam­ag­ing Ex­elix­is shares

8 years ago
R&D

No­var­tis now says that it paid Trump's at­tor­ney $1.2M — and then throws ex-CEO Joe Jimenez un­der the bus

8 years ago
Bioregnum
Opinion

Fin­land's Faron ham­mered by sur­pris­ing piv­otal tri­al flop; CFO Si­mon Dinge­mans ex­its GSK in lead­er­ship makeover

8 years ago
News Briefing

Iron­wood pleas with in­vestors: Don't give us Alex Den­ner

8 years ago
Pharma

Genen­tech al­lies with a metage­nomics up­start in New York on a dis­cov­ery deal jam packed with biobucks

8 years ago
Pharma

Ex-Re­cep­tos CTO co-founds SD start­up Escient, launch­ing with $40M Se­ries A

8 years ago
Financing
Startups
First page Previous page 1036103710381039104010411042 Next page Last page
A service from the Financial Times